Results 171 to 180 of about 132,795 (279)

The Promise of Integration of HIV Into Primary Care: Challenges and Opportunities

Journal of the International AIDS Society, Volume 29, Issue 3, March 2026.
ABSTRACT Introduction Remarkable progress has been made in response to the global HIV epidemic, yet critical gaps and inequities remain, combined with challenges stemming from the current threats to global funding, complacency and competing global health priorities.
Wafaa M. El‐Sadr, Joey Platt
wiley   +1 more source

Diastolic Dysfunction with Vascular Deficits in HIV-1-Infected Female Humanized Mice Treated with Antiretroviral Drugs. [PDF]

Int J Mol Sci
Alomar FA, Dash PK, Ramasamy M, Venn ZL, Bidasee SR, Zhang C, Hackfort BT, Gorantla S, Bidasee KR.   +8 more
europepmc   +1 more source

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function. [PDF]

Front Pharmacol, 2023
Huang C, Hoque T, Bendayan R.
europepmc   +1 more source

High prevalence of low-level viremia among infants initiated on antiretroviral drugs following mother-to-child transmission of HIV. [PDF]

AIDS Res Ther
Nankya I, Natukunda E, Rutebarika D, Matama C, Basiimwa R, Arikod P, Muwabe F, Otike C, Kityo C.   +8 more
europepmc   +2 more sources

Efficacy assessment of antiretroviral drugs against equine infectious anemia virus in vitro. [PDF]

Virus Res
Schimmich C, Vabret A, Valle-Casuso JC.
europepmc   +1 more source

The capacity of HIV in the blood and the cerebrospinal fluid depending on antiretroviral drugs. [PDF]

J Med Life, 2022
Boiko YI, Moskaliuk VD, Randuk YO, Balaniuk IV, Rudan IV, Kolotylo TR, Melenko SR.   +6 more
europepmc   +1 more source

Inflammatory Biomarkers Decay After First‐Line Antiretroviral Therapy Initiation With Dolutegravir/Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide in Persons With HIV: A Substudy of a Randomized Clinical Trial

Health Science Reports, Volume 9, Issue 3, March 2026.
Analuz Fernandez, Sofía Scevola, Raul Rigo Bonin, Maria Saumoy, Arkaitz Imaz, Daniel Podzamczer, Juan Tiraboschi   +6 more
wiley   +1 more source

CD4‐Based Chimeric Antigen Receptor (CAR)‐T Cells With Resistance to HIV‐1 Infection and Enhanced Anti‐HIV Efficacy: Covalent Interaction Between CD4‐CAR and HIV‐1 Envelope Glycoprotein

Journal of Medical Virology, Volume 98, Issue 3, March 2026.
ABSTRACT The current highly active antiretroviral therapy (HAART or ART) effectively suppresses de novo HIV‐1 infection but fails to eliminate HIV reservoir cells, which leads to rapid viral rebound upon ART cessation. Chimeric antigen receptor (CAR) T cells engineered to target HIV‐1 Env⁺ cells offer a promising strategy to eliminate or control these ...
Yaoxian Lou, Xiuting He, Guangming Li, Martin Sikhondze, Jianping Ma, Hongwei Du, Xin Ouyang, Gianpietro Dotti, Mohammad Sajadi, Lishan Su   +9 more
wiley   +1 more source

Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses. [PDF]

AIDS Behav, 2023
Wiesner A, Skrońska M, Gawlik G, Marcinkowska M, Zagrodzki P, Paśko P.   +5 more
europepmc   +1 more source

India's Health Diplomacy: Advancing Pharmaceutical and MedTech Leadership in the Global South

World Medical &Health Policy, Volume 18, Issue 1, March 2026.
ABSTRACT Health diplomacy has become a pivotal aspect of India's engagement with the Global South, intertwining foreign policy, public health, and global collaboration to address disparities while pursuing strategic interests. India's pharmaceutical industry, which accounts for nearly 20% of the world's generics, has positioned the nation as the ...
Gaurav Chanderprakash Mittal, Vijay Kumar Chattu, Prakash Narayanan, Rahul Clare, Cherian Varghese   +4 more
wiley   +1 more source